ANCA-Associated Vasculitis: Core Curriculum 2020
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopi...
Gespeichert in:
Veröffentlicht in: | American journal of kidney diseases 2020-01, Vol.75 (1), p.124-137 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 137 |
---|---|
container_issue | 1 |
container_start_page | 124 |
container_title | American journal of kidney diseases |
container_volume | 75 |
creator | Geetha, Duvuru Jefferson, J. Ashley |
description | Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV. |
doi_str_mv | 10.1053/j.ajkd.2019.04.031 |
format | Article |
fullrecord | <record><control><sourceid>elsevier_webof</sourceid><recordid>TN_cdi_webofscience_primary_000503198700017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638619308261</els_id><sourcerecordid>S0272638619308261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-1dc358ac1056f4d343a8d8b4356fe0e34a89292959b367b895aefab913bdedd43</originalsourceid><addsrcrecordid>eNqNkMtKxDAUhoMozjj6Ai6ke2lNcpo0FTeleINBN-o2pEkKqTPTIWkV394M1VmKZJEL_3dOvoPQOcEZwQyuukx17yajmJQZzjMM5ADNCaOQcgHiEM0xLWjKQfAZOgmhwxiXwPkxmgEBJoCQOcLVU12lVQi9dmqwJnlTQY8rN7hwndS9t0k9eu_i07hOKKb4FB21ahXs2c--QK93ty_1Q7p8vn-sq2WqGWFDSoyOLZSOH-VtbiAHJYxocohXiy3kSpQ0LlY2wItGlEzZVjUlgcZYY3JYIDrV1b4PwdtWbr1bK_8lCZY7fdnJnb7c6Uucy6gfoYsJ2o7N2po98usbA5dT4NM2fRu0sxtt97E4IBbLlKKIJ1LEtPh_unaDGly_qftxM0T0ZkJtnNGHs17-4MZ5qwdpeveXyDd0aood</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ANCA-Associated Vasculitis: Core Curriculum 2020</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Geetha, Duvuru ; Jefferson, J. Ashley</creator><creatorcontrib>Geetha, Duvuru ; Jefferson, J. Ashley</creatorcontrib><description>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2019.04.031</identifier><identifier>PMID: 31358311</identifier><language>eng</language><publisher>PHILADELPHIA: Elsevier Inc</publisher><subject>anti-neutrophil cytoplasmic antibody (ANCA) ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy ; Antibodies, Antineutrophil Cytoplasmic - immunology ; autoantibody ; Churg-Strauss Syndrome - genetics ; Churg-Strauss Syndrome - immunology ; Churg-Strauss Syndrome - pathology ; Churg-Strauss Syndrome - therapy ; complement ; cyclophosphamide ; Cyclophosphamide - therapeutic use ; Disease Progression ; glomerulonephritis ; Glomerulonephritis - genetics ; Glomerulonephritis - immunology ; Glomerulonephritis - pathology ; Glomerulonephritis - therapy ; Glucocorticoids - therapeutic use ; granulomatosis with polyangiitis (GPA) ; Granulomatosis with Polyangiitis - genetics ; Granulomatosis with Polyangiitis - immunology ; Granulomatosis with Polyangiitis - pathology ; Granulomatosis with Polyangiitis - therapy ; Humans ; immunosuppression ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation ; Life Sciences & Biomedicine ; microscopic polyangiitis (MPA) ; Microscopic Polyangiitis - genetics ; Microscopic Polyangiitis - immunology ; Microscopic Polyangiitis - pathology ; Microscopic Polyangiitis - therapy ; Mycophenolic Acid - therapeutic use ; Myeloblastin - immunology ; Peroxidase - immunology ; Remission Induction ; Renal Dialysis ; review ; rituximab ; Rituximab - therapeutic use ; Science & Technology ; Urology & Nephrology ; Vasculitis</subject><ispartof>American journal of kidney diseases, 2020-01, Vol.75 (1), p.124-137</ispartof><rights>2019 National Kidney Foundation, Inc.</rights><rights>Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>251</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000503198700017</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c515t-1dc358ac1056f4d343a8d8b4356fe0e34a89292959b367b895aefab913bdedd43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2019.04.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31358311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geetha, Duvuru</creatorcontrib><creatorcontrib>Jefferson, J. Ashley</creatorcontrib><title>ANCA-Associated Vasculitis: Core Curriculum 2020</title><title>American journal of kidney diseases</title><addtitle>AM J KIDNEY DIS</addtitle><addtitle>Am J Kidney Dis</addtitle><description>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.</description><subject>anti-neutrophil cytoplasmic antibody (ANCA)</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy</subject><subject>Antibodies, Antineutrophil Cytoplasmic - immunology</subject><subject>autoantibody</subject><subject>Churg-Strauss Syndrome - genetics</subject><subject>Churg-Strauss Syndrome - immunology</subject><subject>Churg-Strauss Syndrome - pathology</subject><subject>Churg-Strauss Syndrome - therapy</subject><subject>complement</subject><subject>cyclophosphamide</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Disease Progression</subject><subject>glomerulonephritis</subject><subject>Glomerulonephritis - genetics</subject><subject>Glomerulonephritis - immunology</subject><subject>Glomerulonephritis - pathology</subject><subject>Glomerulonephritis - therapy</subject><subject>Glucocorticoids - therapeutic use</subject><subject>granulomatosis with polyangiitis (GPA)</subject><subject>Granulomatosis with Polyangiitis - genetics</subject><subject>Granulomatosis with Polyangiitis - immunology</subject><subject>Granulomatosis with Polyangiitis - pathology</subject><subject>Granulomatosis with Polyangiitis - therapy</subject><subject>Humans</subject><subject>immunosuppression</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Transplantation</subject><subject>Life Sciences & Biomedicine</subject><subject>microscopic polyangiitis (MPA)</subject><subject>Microscopic Polyangiitis - genetics</subject><subject>Microscopic Polyangiitis - immunology</subject><subject>Microscopic Polyangiitis - pathology</subject><subject>Microscopic Polyangiitis - therapy</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Myeloblastin - immunology</subject><subject>Peroxidase - immunology</subject><subject>Remission Induction</subject><subject>Renal Dialysis</subject><subject>review</subject><subject>rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>Science & Technology</subject><subject>Urology & Nephrology</subject><subject>Vasculitis</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkMtKxDAUhoMozjj6Ai6ke2lNcpo0FTeleINBN-o2pEkKqTPTIWkV394M1VmKZJEL_3dOvoPQOcEZwQyuukx17yajmJQZzjMM5ADNCaOQcgHiEM0xLWjKQfAZOgmhwxiXwPkxmgEBJoCQOcLVU12lVQi9dmqwJnlTQY8rN7hwndS9t0k9eu_i07hOKKb4FB21ahXs2c--QK93ty_1Q7p8vn-sq2WqGWFDSoyOLZSOH-VtbiAHJYxocohXiy3kSpQ0LlY2wItGlEzZVjUlgcZYY3JYIDrV1b4PwdtWbr1bK_8lCZY7fdnJnb7c6Uucy6gfoYsJ2o7N2po98usbA5dT4NM2fRu0sxtt97E4IBbLlKKIJ1LEtPh_unaDGly_qftxM0T0ZkJtnNGHs17-4MZ5qwdpeveXyDd0aood</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Geetha, Duvuru</creator><creator>Jefferson, J. Ashley</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202001</creationdate><title>ANCA-Associated Vasculitis: Core Curriculum 2020</title><author>Geetha, Duvuru ; Jefferson, J. Ashley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-1dc358ac1056f4d343a8d8b4356fe0e34a89292959b367b895aefab913bdedd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>anti-neutrophil cytoplasmic antibody (ANCA)</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy</topic><topic>Antibodies, Antineutrophil Cytoplasmic - immunology</topic><topic>autoantibody</topic><topic>Churg-Strauss Syndrome - genetics</topic><topic>Churg-Strauss Syndrome - immunology</topic><topic>Churg-Strauss Syndrome - pathology</topic><topic>Churg-Strauss Syndrome - therapy</topic><topic>complement</topic><topic>cyclophosphamide</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Disease Progression</topic><topic>glomerulonephritis</topic><topic>Glomerulonephritis - genetics</topic><topic>Glomerulonephritis - immunology</topic><topic>Glomerulonephritis - pathology</topic><topic>Glomerulonephritis - therapy</topic><topic>Glucocorticoids - therapeutic use</topic><topic>granulomatosis with polyangiitis (GPA)</topic><topic>Granulomatosis with Polyangiitis - genetics</topic><topic>Granulomatosis with Polyangiitis - immunology</topic><topic>Granulomatosis with Polyangiitis - pathology</topic><topic>Granulomatosis with Polyangiitis - therapy</topic><topic>Humans</topic><topic>immunosuppression</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Transplantation</topic><topic>Life Sciences & Biomedicine</topic><topic>microscopic polyangiitis (MPA)</topic><topic>Microscopic Polyangiitis - genetics</topic><topic>Microscopic Polyangiitis - immunology</topic><topic>Microscopic Polyangiitis - pathology</topic><topic>Microscopic Polyangiitis - therapy</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Myeloblastin - immunology</topic><topic>Peroxidase - immunology</topic><topic>Remission Induction</topic><topic>Renal Dialysis</topic><topic>review</topic><topic>rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>Science & Technology</topic><topic>Urology & Nephrology</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geetha, Duvuru</creatorcontrib><creatorcontrib>Jefferson, J. Ashley</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geetha, Duvuru</au><au>Jefferson, J. Ashley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANCA-Associated Vasculitis: Core Curriculum 2020</atitle><jtitle>American journal of kidney diseases</jtitle><stitle>AM J KIDNEY DIS</stitle><addtitle>Am J Kidney Dis</addtitle><date>2020-01</date><risdate>2020</risdate><volume>75</volume><issue>1</issue><spage>124</spage><epage>137</epage><pages>124-137</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.</abstract><cop>PHILADELPHIA</cop><pub>Elsevier Inc</pub><pmid>31358311</pmid><doi>10.1053/j.ajkd.2019.04.031</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0272-6386 |
ispartof | American journal of kidney diseases, 2020-01, Vol.75 (1), p.124-137 |
issn | 0272-6386 1523-6838 |
language | eng |
recordid | cdi_webofscience_primary_000503198700017 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | anti-neutrophil cytoplasmic antibody (ANCA) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy Antibodies, Antineutrophil Cytoplasmic - immunology autoantibody Churg-Strauss Syndrome - genetics Churg-Strauss Syndrome - immunology Churg-Strauss Syndrome - pathology Churg-Strauss Syndrome - therapy complement cyclophosphamide Cyclophosphamide - therapeutic use Disease Progression glomerulonephritis Glomerulonephritis - genetics Glomerulonephritis - immunology Glomerulonephritis - pathology Glomerulonephritis - therapy Glucocorticoids - therapeutic use granulomatosis with polyangiitis (GPA) Granulomatosis with Polyangiitis - genetics Granulomatosis with Polyangiitis - immunology Granulomatosis with Polyangiitis - pathology Granulomatosis with Polyangiitis - therapy Humans immunosuppression Immunosuppressive Agents - therapeutic use Kidney Transplantation Life Sciences & Biomedicine microscopic polyangiitis (MPA) Microscopic Polyangiitis - genetics Microscopic Polyangiitis - immunology Microscopic Polyangiitis - pathology Microscopic Polyangiitis - therapy Mycophenolic Acid - therapeutic use Myeloblastin - immunology Peroxidase - immunology Remission Induction Renal Dialysis review rituximab Rituximab - therapeutic use Science & Technology Urology & Nephrology Vasculitis |
title | ANCA-Associated Vasculitis: Core Curriculum 2020 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T02%3A21%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANCA-Associated%20Vasculitis:%20Core%20Curriculum%202020&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Geetha,%20Duvuru&rft.date=2020-01&rft.volume=75&rft.issue=1&rft.spage=124&rft.epage=137&rft.pages=124-137&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2019.04.031&rft_dat=%3Celsevier_webof%3ES0272638619308261%3C/elsevier_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31358311&rft_els_id=S0272638619308261&rfr_iscdi=true |